The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer

Seminars in Radiation Oncology

Volumn 12, Issue 4, 2002, Pages 296-304

  Xia, Fen ^a   Powell, Simon N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOTOXIC AGENT; DNA; GENE PRODUCT; PROTEIN P53;

APOPTOSIS; BREAST CANCER; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; FEMALE; GENE DISRUPTION; GENE LOSS; GENE OVEREXPRESSION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW; RISK FACTOR;

EID: 0036796887     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2002.35250     Document Type: Article

References (81)

1. Hall JM, Lee MK, Newman B, et al: Linkage of earlyonset familial breast cancer to chromosome 17q21. Science 250:1684-1689, 1990
2. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994
3. Chappuis PO, Nethercot V, Foulkes WD: Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18:287-295, 2000
4. Deng CX., Brodie SG: Roles of BRCA1 and its interacting proteins [review]. Bioessays 22:728-737, 2000
5. Parvin JD: BRCA1 at a branch point. Proc Natl Acad Sci U S A 98: 5952-5954, 2001
6. Xu X, Weaver Z, Linke SP, et al: Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3:389-395, 1999
7. Scully R, Ganesan S, Vlasakova K, et al: Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 4:1093-1099, 1999
8. Wang H, Zeng Z, Bui T, et al: Non homologous endjoining of ionizing radiation-induced DNA double strand breaks in human tumor cells deficient in BRCAI or BRCA2. Cancer Res 61:270-277, 2001
9. Moynahan ME, Pierce AJ, Jasin M: Brca2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7:263-272, 2001
10. Taghian DG, Nickoloff JA: Chromosomal double-strand breaks induce gene conversion at high frequency in mammalian cells. Mol Cell Biol 17:6386-6393, 1997
11. DiBiase SJ, Zeng ZC, Chen R, et al: DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res 60:1245-1253, 2000
12. Xu B, Kim S, Kastan MB: Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 21:3445-3450, 2001
13. Lehmann AR, Arlett CF, Burke JF, et al: A derivative of an ataxia-tanlangiectasia (A-T) cell line withnormal radiosensitivity but A-T-like inhibition of DNA synthesis. Iht J Radiat Biol 49:639-643, 1986
14. Gowen LC, Avrutskaya AV, Latour AM, et al: BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281:1009-1012, 1998
15. Moynahan ME, Cui TY, Jasin M: Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brcal mutation. Cancer Res 61:4842-4850, 2001
16. Thangaraju M, Kaufmann SH, Couch FJ: BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 275:33487-33496, 2000
17. Rahman N, Stratton MR: The genetics of breast cancer susceptibility. Annu Rev Genet 32:95-121, 1998
18. Xia F, Taghian DG, DeFrank JS, et al: Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A 98:8644-8649, 2001
19. Yu V, Koehler M, Steinlein C, et al: Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Gene Dev 14:1400-1406, 2000
20. Chen J, Silver DP, Walpita D, et al: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 2:317-328, 1998
21. Chen PL, Chen CF, Chen Y, et al: The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 95:5287-5292, 1998
22. Davies AA, Masson JY, McIlwraith MJ, et al: Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7:273-282, 2001
23. Chen CF, Chen PL, Zhong Q, et al: Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control. J Biol Chem 274:32931-32935, 1999
24. Kastan MB, Lim DS, Kim ST, et al: ATM-a key determinant of multiple cellular responses to irradiation. Acta Oncologica 40:686-688, 2001
25. Angele S, Hall J: The ATM gene and breast cancer: Is it really a risk factor? Mutat Res 462:167-178, 2000
26. Swift M, Reitnauer PJ, Morrell D, et al: Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316:1289-1294, 1987
27. Swift M, Morrell PJ, Cromartie E, et al: The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 39:573-583, 1986
28. Iau PTC, Macmillan RD, Blamey RW: Germline mutations associated with breast cancer susceptibility. Eur J Cancer 37:300-321, 2001
29. Jongmans W, Hall J: Cellular responses to radiation and risk of breast cancer. Eur J Cancer 35:540-548, 1999
30. Khanna KK: Cancer risk and the ATM gene: A continuing debate. J Natl Cancer Inst 92:795-802, 2000
31. Badie G, Iliakis G, Foray G, et al: Induction and rejoining of DNA double-strand breaks and interphase chromosome breaks after exposure to x-ray in one normal and two hypersensitive human fibroblast cell lines. Radiat Res 144:26-35, 1995
32. Mitchell EL, Scott D: G2 chromosomal sensitivity in fibroblast of ataxia-telangiectasia heterozygotes and Li-Fraumeni syndrome patient with radioresistant cells. Intl J Radiat Biol 72:435-438, 1997
33. Bernstein JL, Lopez-Carrillo L, Wang L: The epidemiology of Her-2/neu and P53 in breast cancer. Salud Publica de Mexico 41:S114-S123, 1999
34. Bergh J: Clinical studies of p53 in treatment and benefit of breast cancer patients. Endocr-Relat Cancer 6:51-59, 1999
35. Phillips HA: The role of the p53 tumour suppressor gene in human breast cancer. Clin Oncol UK 11:148-155, 1999
36. Ingvarsson S: Molecular genetics of breast cancer progression. Semin Cancer Biol 9:277-288, 1999
37. Chariyalertsak S, Cheirsilpa A, Chindavijak K: Prognostic importance of p53 and c-erbB-2 oncoproteins overexpression in patients with breast cancer. J Med Assoc Thailand 81:698-704, 1998
38. Buchholz TA, Weil MM, Story MD, et al: Tumor suppressor genes and breast cancer. Radiat Oncol Investig 7:55-65, 1999
39. Crook T, Crossland S, Crompton MR, et al: p53 mutations in BRCA1-associated familial breast cancer [letter; see comments]. Lancet 350:638-639, 1997
40. Crook T, Brooks LA, Crossland S, et al: p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 17:1681-1689, 1998
41. Eisinger F, Jacquemier J, Guinebretiere JM, et al: p53 involvement in BRCA1-associated breast cancer [letter; comment]. Lancet 350:1101, 1997
42. Ingvarsson S: Molecular genetics of breast cancer progression [Review]. Semin Cancer Biol 9:277-288, 1999
43. Irminger-Finger I, Siegel BD, Leung WC: The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins. Biol Chem 380:117-128, 1999
44. Kennedy AS, Harrison GH, Mansfield CM, et al: Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: Effect of TP53 or hMLH1 deficiency. Intl J Cancer 90:175-185, 2000
45. Matsui Y, Tsuchida Y, Keng PC: Effects of p53 mutations on cellular sensitivity to ionizing radiation. Am J Clin Oncol 24:486-490, 2001
46. Chang PY, Kanazawa N, Lutze-Mann L, et al: p53 deficiency alters the yield and spectrum of radiation-induced lacZ mutants in the brain of transgenic mice. Mutagenesis 16:7-15, 2001
47. Kawabe S, Roth JA, Wilson DR, et al: Adenovirus-mediated pl6INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene 19:5359-5366, 2000
48. Miyata H, Doki Y, Shiozaki H, et al: CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res 6:4859-4865, 2000
49. Rosen EM, Fan S, Goldberg ID, et al: Biological basis of radiation sensitivity: Part 2. Cellular and molecular determinants of radiosensitivity. Oncology (Huntington) 14:741-757; discussion 757-766, 2000
50. Schwartz JL, Jordan R, Kaufmann WK, et al: Evidence for the expression of radiation-induced potentially lethal damage being a p53-dependent process. Intl J Radiat Biol 76:1037-1043, 2000
51. Lawrence TS, Burke R, Davis MA: Lack of effect of TP53 status on fluorodeoxyuridine-mediated radiosensitization. Radiat Res 154:140-144, 2000
52. Chen M, Hough AM, Lawrence TS: The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemoth Pharm 45:369-374, 2000
53. Obata A, Eura M. Sasaki J, et al: Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Intl J Cancer 89:187-193, 2000
54. Wouters BG, Denko NC, Giaccia AJ, et al: A p53 and apoptotic independent role for p21wafl in tumour response to radiation therapy. Oncogene 18:6540-6545, 1999
55. Gruninger L, Cottin E, Li YX, et al: Sensitizing human cervical cancer cells in vitro to ionizing radiation with interferon beta or gamma. Radiat Res 152:493-498, 1999
56. Bache M, Dunst J, Wurl P, et al: G2/M checkpoint is p53-dependent and independent after irradiation in five human sarcoma cell lines. Anticancer Res 19:1827-1832, 1999
57. Schwartz JL, Rasey J, Wiens L, et al: Functional inactivation of p53 by HPV-E6 transformation is associated with a reduced expression of radiation-induced potentially lethal damage. Intl J Radiat Biol 75:285-291, 1999
58. Pestell KE, Medlow CJ, Titley JC, et al: Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Intl J Cancer 77:913-918, 1998
59. Willers H, McCarthy EE, Wu B, et al: Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. Oncogene 19: 632-639, 2000
60. Xia F, Liber HL: The tumor suppressor p53 modifies mutational processes in a human lymphoblastoid cell line. Mutat Res 373:87-97, 1997
61. Wilson CA, Ramos L, Villasenor MR, et al: Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21:236-240, 1999
62. Hedenfalk I, Duggan D, Chen Y, et al: Gene-expression profiles in hereditary breast cancer. N Engl J Med 344: 539-548, 2001
63. Chen JJ, Silver D, Cantor S, et al: BRCAI, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 59:1752s-1756s, 1999
64. Simon JA, Szankasi P, Nguyen DK, et al: Differential toxicity of anticacer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 60: 328-333, 2000
65. Tsongalis GJ, Ried A Jr: HER2: The neu prognostic marker for breast cancer. Crit Rev Clin Lab Sci 38:167-182, 2001
66. Pegram MD, Konecny G, Slamon DJ: The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103:57-75, 2000
67. Wang SC, Hung MC: HER2 overexpression and cancer targeting. Semin Oncol 28:115-124, 2001
68. Weiner LM: An overview of monoclonal antibody therapy of cancer. Semin Oncol 26:41-50, 1999
69. Dillman RO: Perceptions of Herceptin: A monoclonal antibody for the treatment of breast cancer. Cancer Biother Radiopharm 14:5-10, 1999
70. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in woman with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
71. Pietras RJ, Poen JC, Gallardo D, et al: Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355,1999
72. Tezuka M, Watanabe H, Nakamura S, et al: Antiapoptotic activity is dispensable for insulin-like growth factor I receptor-mediated clonogenic radioresistance after gamma-irradiation. Clin Cancer Res 7:3206-3214, 2001
73. Peretz S, Jensen R, Baserga R, et al: ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci U S A 98:1676-1681, 2001
74. Harari PM, Huang SM: Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11:281-289, 2001
75. Chiarle R, Pagano M, Inghirami G: The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res 3:91-94, 2001
76. Puisieux A: [Cell cycle and breast cancer]. Annales de Pathologie 20:S6-S12, 2000
77. Zhou Q, Hopp T, Fuqua SA, et al: Cyclin D1 in breast premalignancy and early breast cancer: Implications for prevention and treatment, Cancer Lett 162:3-17, 2001
78. Bartelink H, Begg AC, Martin JC, et al: Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am 6:2-10, 2000
79. Zhou Q, Fukushima P, DeGraff W, et al: Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1. Cancer Res 60:2611-2615, 2000
80. Turner BC, Gumbs AA, Carter D, et al: Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. Intl J Radiat Oncol Biol Phys 47:1169-1176, 2000
81. Yoo SS, Carter D, Turner BC, et al: Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Intl J Cancer 90: 22-28, 2000